Analysts expect that Advaxis, Inc. (NASDAQ:ADXS) will post earnings of ($1.37) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Advaxis’ earnings. Advaxis posted earnings per share of ($4.35) during the same quarter last year, which would indicate a positive year-over-year growth rate of 68.5%. The company is scheduled to report its next quarterly earnings report on Thursday, January 9th.

According to Zacks, analysts expect that Advaxis will report full-year earnings of ($2.70) per share for the current financial year. For the next fiscal year, analysts forecast that the firm will report earnings of ($2.41) per share. Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Advaxis.

ADXS has been the topic of a number of recent analyst reports. ValuEngine upgraded Advaxis from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Zacks Investment Research lowered Advaxis from a “buy” rating to a “hold” rating in a research report on Monday.

A number of institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. raised its holdings in Advaxis by 53,633.7% during the second quarter. JPMorgan Chase & Co. now owns 51,047 shares of the biotechnology company’s stock worth $107,000 after purchasing an additional 50,952 shares in the last quarter. Vanguard Group Inc. increased its stake in Advaxis by 71.1% during the 2nd quarter. Vanguard Group Inc. now owns 230,106 shares of the biotechnology company’s stock worth $481,000 after buying an additional 95,607 shares during the period. Finally, Renaissance Technologies LLC increased its position in shares of Advaxis by 143.7% in the 2nd quarter. Renaissance Technologies LLC now owns 501,000 shares of the biotechnology company’s stock worth $1,047,000 after purchasing an additional 295,444 shares during the last quarter. 7.32% of the stock is owned by institutional investors.

NASDAQ ADXS traded down $0.01 during trading hours on Thursday, hitting $0.29. The company had a trading volume of 324,397 shares, compared to its average volume of 13,119,591. Advaxis has a 52 week low of $0.21 and a 52 week high of $11.85. The firm has a 50 day simple moving average of $0.32 and a 200 day simple moving average of $1.84. The firm has a market capitalization of $5.26 million, a price-to-earnings ratio of -0.02 and a beta of 3.16.

About Advaxis

Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer.

Featured Article: How do analysts define an oversold condition?

Get a free copy of the Zacks research report on Advaxis (ADXS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Advaxis (NASDAQ:ADXS)

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.